Stoke Therapeutics Inc (STOK)
13.97
-0.36
(-2.51%)
USD |
NASDAQ |
Jun 25, 16:00
13.97
0.00 (0.00%)
After-Hours: 20:00
Stoke Therapeutics Research and Development Expense (TTM): 84.97M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 84.97M |
| December 31, 2023 | 82.23M |
| September 30, 2023 | 81.51M |
| June 30, 2023 | 81.35M |
| March 31, 2023 | 79.16M |
| December 31, 2022 | 77.84M |
| September 30, 2022 | 72.58M |
| June 30, 2022 | 66.83M |
| March 31, 2022 | 62.56M |
| December 31, 2021 | 54.17M |
| September 30, 2021 | 47.27M |
| Date | Value |
|---|---|
| June 30, 2021 | 41.02M |
| March 31, 2021 | 34.89M |
| December 31, 2020 | 32.20M |
| September 30, 2020 | 30.38M |
| June 30, 2020 | 28.79M |
| March 31, 2020 | 26.84M |
| December 31, 2019 | 23.76M |
| September 30, 2019 | 19.68M |
| June 30, 2019 | 15.39M |
| March 31, 2019 | 11.25M |
| December 31, 2018 | 8.371M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
15.39M
Minimum
Jun 2019
84.97M
Maximum
Mar 2024
52.17M
Average
50.72M
Median
Research and Development Expense (TTM) Benchmarks
| iBio Inc | 6.401M |
| Lixte Biotechnology Holdings Inc | 0.8281M |
| Fate Therapeutics Inc | 139.10M |
| Ocular Therapeutix Inc | 67.04M |
| Viking Therapeutics Inc | 76.90M |